Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis
Status:
Completed
Trial end date:
2020-10-15
Target enrollment:
Participant gender:
Summary
ATLANTIS is a multicenter, phase IIIb, prospective, open-label, randomized trial.
The objective of this study is to demonstrate superiority of a strategy of anticoagulation
with apixaban (Anti-Xa Group) as compared to the current standard of care in patients who
have undergone a successful TAVI procedure.
The randomization is stratified according to the presence or not of a mandatory indication
for anticoagulation for a reason other than the TAVI procedure (e.g. atrial fibrillation or
DVT/PE).
Phase:
Phase 3
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborators:
Action Research Group Bristol-Meyers Squibb & Pfizer